Top

Current Atherosclerosis Reports

Published in:

Open Access 29-08-2023 | Coronary Heart Disease

Updates in Drug Treatment of Severe Hypertriglyceridemia

Authors: Ioanna Gouni-Berthold, Jonas Schwarz, Heiner K. Berthold

Published in: Current Atherosclerosis Reports | Issue 10/2023

Abstract

Purpose of Review

To provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG).

Recent Findings

sHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeting APOC3 and ANGPTL3. The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen.

Summary

The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezarsen, an N-acetylgalactosamine (GalNAc)-conjugated ASO with the same target, seems to have a better safety and efficacy profile. siRNA targeting APOC3 and ANGPTL3, namely ARO-APOC3 and ARO-ANG3, are also promising for the treatment of sHTG. However, the ultimate clinical goal of any sHTG treatment, the decrease in the risk of AP, has not been definitively achieved till now by any pharmacotherapy, either approved or in development.

• Lazarte J, Hegele RA. Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Rev Cardiovasc Ther. 2021;19:685–93. https://doi.org/10.1080/14779072.2021.1955348. An excellent review of the role of volanesorsen in the treatment of FCS.CrossRefPubMed

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:E1082–143. https://doi.org/10.1161/CIR.0000000000000625.CrossRefPubMed

Paquette M, Bernard S. The evolving story of multifactorial chylomicronemia syndrome. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/FCVM.2022.886266.

Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450–61. https://doi.org/10.1016/J.JACL.2012.08.007.CrossRefPubMed

Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15:395–405. https://doi.org/10.1080/17512433.2022.2094768.CrossRefPubMed

Wolska A, Yang ZH, Remaley AT. Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol. 2020;31:331–9. https://doi.org/10.1097/MOL.0000000000000710.CrossRefPubMedPubMedCentral

Goldberg A, Alagona P, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85:1100–5. https://doi.org/10.1016/S0002-9149(00)00703-7.CrossRefPubMed

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRefPubMed

Spagnuolo CM, Hegele RA. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Expert Opin Pharmacother. 2023;24:1013–20. https://doi.org/10.1080/14656566.2023.2206015.CrossRefPubMed

10.

Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41. https://doi.org/10.1056/NEJMoa1308027.CrossRefPubMed

11.

TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung and BI, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31. https://doi.org/10.1056/NEJMoa1307095.

12.

•• Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381:531–42. https://doi.org/10.1056/NEJMoa1715944. A phase 3, randomized controlled trial on the efficacy and safety of volanesorsen in patients with FCS.CrossRefPubMed

13.

• Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023;17. https://doi.org/10.1016/J.JACL.2023.03.007. An open-label extension trial examining the long-term efficacy and safety of volanesorsen in patients with FCS.

14.

• Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. lancet Diabetes Endocrinol. 2021;9:264–75. https://doi.org/10.1016/S2213-8587(21)00046-2. A phase 3, randomized controlled trial on the efficacy and safety of volanesorsen in patients with MCM.

15.

Prohaska TA, Alexander VJ, Karwatowska-Prokopczuk E, Tami J, Xia S, Witztum JL, et al. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. J Clin Lipidol. 2023;17. https://doi.org/10.1016/J.JACL.2023.04.007.

16.

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408–15. https://doi.org/10.2337/DC16-0126.CrossRefPubMed

17.

Oral EA, Garg A, Tami J, Huang EA, O’Dea LSL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study. J Clin Lipidol. 2022;16:833–49. https://doi.org/10.1016/J.JACL.2022.08.008.CrossRefPubMed

18.

Jones A, Peers K, Wierzbicki AS, Ramachandran R, Mansfield M, Dawson C, et al. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Atherosclerosis. 2023;375:67–74. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2023.05.008.CrossRefPubMed

19.

Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J. 2022;43:1413–5. https://doi.org/10.1093/EURHEARTJ/EHAB890.CrossRefPubMed

20.

• Tardif J-C, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401–12. https://doi.org/10.1093/eurheartj/ehab820. Assessment of the clinical efficacy and safety of olezarsen in patients with moderate HTG.

21.

Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022;16:617–25. https://doi.org/10.1016/J.JACL.2022.06.005.CrossRefPubMed

22.

McGarrah RW, Craig DM, Haynes C, Dowdy ZE, Shah SH, Kraus WE. High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis. 2016;246:229–35. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2016.01.012.CrossRefPubMedPubMedCentral

23.

A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE). Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04568434. Accessed 9 Jul. 2023.

24.

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia. Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT05552326. Accessed 9 Jul. 2023.

25.

A Study of ISIS 678354 Administered to Participants With Severe Hypertriglyceridemia. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05079919. Accessed 9 Jul. 2023.

26.

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia. Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT05355402. Accessed 9 Jul. 2023.

27.

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia. Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT05610280. Accessed 9 Jul. 2023.

28.

• Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, et al. Abstract 12594: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia. Circulation. 2020;142. https://doi.org/10.1161/CIRC.142.SUPPL_3.12594. Preliminary results from a phase 1 trial evaluating the efficacy and safety of ARO-APOC3 in patients with HTG and MCM.

29.

• Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, et al. Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia. Circulation. 2021;144. https://doi.org/10.1161/CIRC.144.SUPPL_1.10357. Results from a phase 1 trial evaluating the efficacy and safety of ARO-APOC3 in patients with severe HTG.

30.

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR). Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT04998201. Accessed 9 Jul. 2023.

31.

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2). Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04720534. Accessed 9 Jul. 2023.

32.

Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE). Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT05089084. Accessed 9 Jul. 2023.

33.

Ng DS. Evolving ANGPTL-based lipid-lowering strategies and beyond. Curr Opin Lipidol. 2021;32:271–2. https://doi.org/10.1097/MOL.0000000000000764.CrossRefPubMed

34.

Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211–21. https://doi.org/10.1056/NEJMoa1612790.CrossRefPubMedPubMedCentral

35.

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03747224. Accessed 9 Jul. 2023.

36.

Watts G, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia. Eur Heart J. 2020;41(Suppl):2. https://doi.org/10.1093/EHJCI/EHAA946.3331.CrossRef

37.

•• Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. Abstract 15751: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia. Circulation. 2020;142. https://doi.org/10.1161/CIRC.142.SUPPL_3.15751. Preliminary results from a phase 1 study evaluating the efficacy and safety of ARO-ANG3 in patients with hypercholesterolemia.

38.

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2). Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04832971. Accessed 9 Jul. 2023.

39.

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) (Gateway). Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT05217667. Accessed 9 Jul. 2023.

40.

Chen YQ, Pottanat TG, Siegel RW, Ehsani M, Qian YW, Zhen EY, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61:1203–20. https://doi.org/10.1194/JLR.RA120000781.CrossRefPubMedPubMedCentral

41.

Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, Stitziel NO, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94:223–32. https://doi.org/10.1016/J.AJHG.2014.01.009.CrossRefPubMedPubMedCentral

42.

A Study of LY3475766 in Healthy Participants. Clinicaltrials.gov. https://www.clinicaltrials.gov/study/NCT04052594. Accessed 9 Jul. 2023.

43.

Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29. https://doi.org/10.1038/S41591-023-02222-W.

44.

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04863014. Accessed 9 Jul. 2023.

45.

Graham MJ, Lee RG, Brandt TA, Tai L-J, Fu W, Peralta R, et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017;377:222–32. https://doi.org/10.1056/NEJMoa1701329.CrossRefPubMed

46.

Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41:3936–45. https://doi.org/10.1093/eurheartj/ehaa689.CrossRefPubMedPubMedCentral

47.

Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377–86. https://doi.org/10.1161/CIRCULATIONAHA.122.059266.CrossRefPubMedPubMedCentral

48.

Minicocci I, Montali A, Robciuc MR, Quagliarini F, Censi V, Labbadia G, et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2012;97:E1266–75. https://doi.org/10.1210/jc.2012-1298.CrossRefPubMedPubMedCentral

49.

Ke Y, Liu S, Zhang Z, Hu J. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis. 2021;20. https://doi.org/10.1186/S12944-021-01481-1.

50.

Whittaker MN, Musunuru K. Therapeutic application of genome editing in dyslipidemia. Curr Opin Lipidol. 2022;33:133–8. https://doi.org/10.1097/MOL.0000000000000805.CrossRefPubMed

Title: Updates in Drug Treatment of Severe Hypertriglyceridemia
Authors: Ioanna Gouni-Berthold
Jonas Schwarz
Heiner K. Berthold
Publication date: 29-08-2023
Publisher: Springer US
Keywords: Coronary Heart Disease
Acute Pancreatitis
Circulatory Disease
Dyslipidemia
Published in: Current Atherosclerosis Reports / Issue 10/2023
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-023-01140-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Updates in Drug Treatment of Severe Hypertriglyceridemia

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 10/2023

Fixed Combination for the Treatment of Dyslipidaemia

The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review

The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis

Promoting Cardiovascular Health in the Community: Training the Next Generation of Scientists in the Jackson Heart Study

The TICE Pathway: Mechanisms and Potential Clinical Applications

Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries